# Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients

> **NCT04578834** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 518 (actual)

## Conditions studied

- IgA Nephropathy

## Interventions

- **DRUG:** Placebo
- **DRUG:** LNP023

## Key facts

- **NCT ID:** NCT04578834
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-25
- **Primary completion:** 2025-09-19
- **Final completion:** 2025-09-19
- **Target enrollment:** 518 (ACTUAL)
- **Last updated:** 2025-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04578834

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04578834, "Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04578834. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*